Navigation Links
Lentigen Licenses Fundamental Lentiviral Vector Technology Patent From the University of Cambridge
Date:4/3/2008

BALTIMORE, April 3, 2008 /PRNewswire/ -- Lentigen Corporation today announced an exclusive licensing agreement with Cambridge Enterprise, the organization responsible for licensing technologies from the University of Cambridge (U.K.), for a fundamental patent in the area of lentiviral vector technology. The technology was developed in the laboratory of Professor Andrew Lever at the University of Cambridge.

"The patent broadly claims fundamental compositions of HIV-based lentiviral vectors that are currently widely used in research and clinical studies," said Boro Dropulic, Ph.D., founder, president and chief scientific officer of Lentigen. He added "we are delighted to be working with Professor Lever in obtaining this patent license, and developing its application in biomedicine."

Following the acquisition of the Cell Genesys' lentiviral patent portfolio late last year by GBP Capital, the majority shareholder in Lentigen, this license further consolidates Lentigen's intellectual property position.

"Licensing this fundamental technology patent from the University of Cambridge extends our strong intellectual property position and is consistent with our goal of becoming a leader in lentiviral-vector based biomedicine. It further enables Lentigen to pursue development and commercialization of biomedical products and services, to the benefit of patients, healthcare providers and the research community," said Tim Ravenscroft, chief executive officer of Lentigen.

"Lentigen are the ideal partner for this piece of fundamental lentiviral vector technology. We are pleased to be working with a team committed to developing the technology for patient benefit," added Dr Andrew Walsh, technology manager for Cambridge Enterprise, University of Cambridge.

About Lentiviral Vectors

Lentiviral vectors (LV) are the most efficient vehicles for stable delivery of genes or gene silencing sequences (e.g. RNAi) into cells. Gene delivery is acco
'/>"/>

SOURCE Lentigen Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Lentigen Corporation Announces Exclusive Licensing Agreement With Case Western Reserve University to Develop Novel Stem-Cell Therapy for Brain Cancer
2. Lentigen to Move Headquarters and Manufacturing to Gaithersburg
3. Lentigen Appoints Tim Ravenscroft as Chief Executive Officer
4. VIRxSYS and Lentigen Announce Litigation Settlement
5. U.S. FDA Licenses DAPTACEL(R) Vaccine for the Fifth Consecutive Dose in the Pediatric DTaP Immunization Series
6. Egenix Licenses Harvard Anti-Cancer Platform
7. NEXCORE Technology Obtains Licenses for Revolutionary Fluid Management System
8. Maxygen Licenses Dengue Vaccine Technology to sanofi pasteur
9. Prometheus Licenses COLAL-PRED(R) From Alizyme
10. Utrecht University Licenses MetaDrug From GeneGo for Drug Innovation
11. Syngenta Licenses Chromatin Gene Stacking Technology

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2009)... Jessica Torrente, Assistant Professor of Radiolog...n Washington, D.C., demonstrated the integration a...clinical practice as an adjunct imaging modality f...ual meeting of the Radiological Society of North A...as to demonstrate how BSGI is used in the clinical...
(Date:11/30/2009)...FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq...dministration (FDA) has granted orphan drug design...dine phosphate, for the rare autoimmune disease La...as previously received orphan drug designation in ... Medicinal Products for Human Use of the European ...
(Date:11/30/2009)...RNewswire/ -- Exiqon A/S (NASDAQ OMX Copenhagen: "...ool ICCB-Longwood Screening Facility (ICCB-L) has ...Excellence. ICCB-L supports investigators at Harv...nstitutions, for high-throughput screening of smal... a novel class of small, non-coding RNA species, w...
(Date:11/30/2009)...DAM, November 30 Elsevie...dical and technical products and services,today a...nsive biomedical,database which holds over 20 mill...eer reviewed journals. , Embase has long ...ical,and pharmaceutical insights. Now, new develop...
Breaking Biology Technology:Breast-Specific Gamma Imaging In Clinical Practice as an Adjunct Imaging Modality for Diagnosis of Breast Cancer 2FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS 2FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS 3FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS 4Exiqon Recognizes Harvard Medical School Core Facility as MicroRNA Screening Center of Excellence 2Exiqon Recognizes Harvard Medical School Core Facility as MicroRNA Screening Center of Excellence 3Elsevier is Re-Launching "Embase" to be a Powerful Resource Providing Deep Insights and Answers to Biomedical Researchers 2Elsevier is Re-Launching "Embase" to be a Powerful Resource Providing Deep Insights and Answers to Biomedical Researchers 3
... a provider of long-term care services in New Eng...Wendy LaBate has been promoted to Senior Vice Pres...r new position, LaBate will be responsible for pro...Genesis, Regional Vice Presidents of Operations an... center operations, improve efficiencies and promo...
...q: CEPH ) announced today that Sarma P. Duddu, P...ce President of Drug Delivery Technologies of CIMA... aspects of the Cephalon drug delivery business at...ocated in suburban Minnesota. , , (Photo: htt... ) , , In his new role, Dr. Duddu will be a membe...
... Institute Pharma,(TI Pharma) has formed a consort...y Medical Centre and Nobilon, a subsidiary of Sch...ine against the Chikungunya virus. This,vaccine ai... Viral disease epidemics have increased in inc...these diseases is caused by the Chikungunya virus,...
Other Biology Technology:Genesis HealthCare Promotes Wendy LaBate To Senior Vice President of Operations for the Northeast Area 2Cephalon Appoints Sarma P. Duddu as General Manager and Vice President of Drug Delivery Technologies for CIMA LABS 2Cephalon Appoints Sarma P. Duddu as General Manager and Vice President of Drug Delivery Technologies for CIMA LABS 3Cephalon Appoints Sarma P. Duddu as General Manager and Vice President of Drug Delivery Technologies for CIMA LABS 4Vaccine Against the Chikungunya Virus in Development by a Public-Private Partnership 2
(Date:11/30/2009)...ratures continue to rise scientists are presented ...ecies respond and adapt. In a paper published in ...odriguez-Trelles and Dr Miguel Rodriguez assess th... of approximately 0.6˚C has already affected ...ng ecologists and evolutionary biologists is to pr...
(Date:11/30/2009)...report published in the December 2009 print issue ...lar type of control over their fertility that wome...sts have found how and where androgenic hormones w...on and male fertility. This opens a promising aven...discovery also offers hope to those who cannot hav...
(Date:11/26/2009)...r impressive antlers, red deer have been caught in... antlers are much more than decorative. They are l...ing. John Currey, from The University of York, UK,...f bone for over half a century and has become fasc...ugh a long-standing collaboration with Tomas Lande...
Breaking Biology News(10 mins):How can scientists measure evolutionary responses to climate change? 2Tough yet stiff deer antler is materials scientist's dream 2Deerfield Spa The Poconos Most Affordable Destination Spa Schedules Ribbon Cutting Event for Grand Opening of New Day Spa 51478 1Deerfield Spa The Poconos Most Affordable Destination Spa Schedules Ribbon Cutting Event for Grand Opening of New Day Spa 51478 2Hologic to Present at the 29th Annual Canaccord Adams Global Growth Conference 51475 1Hush little baby Linking genes brain and behavior in children 9237 1Hush little baby Linking genes brain and behavior in children 9237 2
... New knowledge points to the fact that a genetical... skin barrier, plays a decisive role in the origin...school-children scientists of the Helmholtz Zentru...d that about 8% of the German population carry var...k to develop atopic dermatitis more than threefold...
... Measures for better air , Now that Olympia is ap...educe the air pollution in the large cities with d... Beijing is massively limited: the government has ... Private cars are only allowed to drive on even or...number. Furthermore, legal regulations have been i...
... PHILADELPHIA Based on a pilot study in children ...es of Health (NIH) believe that immunotherapy coul...this cancer. , The researchers tested a novel de...to potentially strengthen the immune system post c...ust 1 issue of Clinical Cancer Research , a journ...
Other Biology News:When our protective armor shows weakness 2GKSS membranes reduce air pollution in Beijing 2Immunotherapy in high-risk pediatric sarcomas shows promising response 2Immunotherapy in high-risk pediatric sarcomas shows promising response 3
...ost comprehensive, cost-effective solution to your...ated unprecedented quality into both our products ...ection chemistries and antibodies that have been o...s our competitively priced accessories that can be...
Mouse Anti-Yellow Fever Virus Monoclonal Antibody, Unconjugated, Clone 3576 from Abcam
Mouse Anti-Human XPMC2H Polyclonal Antibody, Unconjugated from ABR-Affinity BioReagents
Gel Loading Dye (Bromophenol Blue/Glycerol) from Mo Bio Laboratories, Inc.
Biology Products: